Nektar Therapeutics (NKTR)
(Real Time Quote from BATS)
$1.49 USD
-0.15 (-9.15%)
Updated May 28, 2024 12:30 PM ET
3-Hold of 5 3
F Value D Growth A Momentum F VGM
Brokerage Reports
0 items in cart
Nektar Therapeutics [NKTR]
Reports for Purchase
Showing records 101 - 120 ( 394 total )
Company: Nektar Therapeutics
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Nektar Therapeutics
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Nektar Therapeutics
Industry: Medical - Drugs
Model Update: Reiterate Neutral With a $24 Target
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Nektar Therapeutics
Industry: Medical - Drugs
CMC Missteps Seriously Dent Confidence in Management''s Ability to Execute in Oncology; Time for the Board to Step In
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Nektar Therapeutics
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Nektar Therapeutics
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Nektar Therapeutics
Industry: Medical - Drugs
Company: Nektar Therapeutics
Industry: Medical - Drugs
We Would So Like to Believe in Bempeg, but Can''t Quite Get There; NSCLC Remains Our Focus
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Nektar Therapeutics
Industry: Medical - Drugs
Company: Nektar Therapeutics
Industry: Medical - Drugs
Company: Nektar Therapeutics
Industry: Medical - Drugs
Is Bempeg Living up to its Promise in Sarcoma''s; We Are Not Convinced Based on Historic Comparisons
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Nektar Therapeutics
Industry: Medical - Drugs
Company: Nektar Therapeutics
Industry: Medical - Drugs
An Eye out for the Clinically Relevant, But Commercially Unimportant Sarcoma Update at the ASCO
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Nektar Therapeutics
Industry: Medical - Drugs
Company: Nektar Therapeutics
Industry: Medical - Drugs
Company: Nektar Therapeutics
Industry: Medical - Drugs
Company: Nektar Therapeutics
Industry: Medical - Drugs
Catalyst Calendar Pushout; Nothing Jaw Dropping With Bempeg Doublets Hence, Emerging Focus on Triplets
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Nektar Therapeutics
Industry: Medical - Drugs
Heterogenous and Healthier Population Compared to KEYNOTE-052 Meaningfully Complicates Interpretation
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Nektar Therapeutics
Industry: Medical - Drugs
Company: Nektar Therapeutics
Industry: Medical - Drugs
Not Yet Ready to Celebrate the Law of Small Numbers: Awaiting Full Data Update on February 15, 2019
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D